WHO approves Bharat Biotech’s Covaxin for emergency use

Bharat Biotech’s Covaxin has got WHO approval as the technical advisory team has recommended the India-made vaccine for emergency use listing for 18 years and above. This marks a major victory for India’s journey in vaccination against Covid-19. Covaxin is a vaccine, completely ‘made in India’, by Hyderabad-based Bharat Biotech and the Indian Council of Medical Research. WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson 7 Johnson – Janssen, Moderna, and Sinopharm for emergency use.

Buy Prime Test Series for all Banking, SSC, Insurance & other exams

The emergency listing got delayed last month as the technical advisory group sought some additional clarification from Bharat Biotech for its final risk assessment. The technical advisory group met to take the final call, and Covaxin has been recommended for emergency use listing. Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

Important takeaways for all competitive exams:

• WHO Established: 7 April 1948;
• WHO Director General: Dr Tedros Adhanom Ghebreyesus;
• WHO Headquarters: Geneva, Switzerland.

Find More International News